Catalyst

Slingshot members are tracking this event:

Catalyst Pharmaceuticals (CPRX) planning New Drug Application (NDA) submission for Firdapse, a neuronal potassium channel blocker, in Q1 2018

Source Link:
http://seekingalpha.com/article/4055760-catalyst-pharmaceutical-partners-cprx-ceo-pat-mcenany-q4-2016-results-earnings-call

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
CPRX Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details  Update on 30 Aug 2017: Initially expected Q4 20167, NDA submission for Firdapse moves to first quarter 2018 
http://seekingalpha....
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Mar 29, 2018
Occurred Source:
http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=1062314
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Firdapse, Neuronal Potassium Channel Blocker, Nda Filing
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.